ABT-199: Taking Dead Aim at BCL-2

被引：74
作者：
Davids, Matthew S. [1 ]
Letai, Anthony [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
来源：
CANCER CELL | 2013年 / 23卷 / 02期
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; FAMILY; ABT-737;
D O I：
10.1016/j.ccr.2013.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict the efficacy of ABT-199 in individual tumors will be critical in determining how best to incorporate this promising agent into the armamentarium of cancer therapies.
引用
收藏
页码：139 / 141
页数：3
相关论文
共 10 条
[1]   Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members [J].
Certo, Michael ;
Moore, Victoria Del Gaizo ;
Nishino, Mari ;
Wei, Guo ;
Korsmeyer, Stanley ;
Armstrong, Scott A. ;
Letai, Anthony .
CANCER CELL, 2006, 9 (05) :351-365
[2]   Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy [J].
Chonghaile, Triona Ni ;
Sarosiek, Kristopher A. ;
Thanh-Trang Vo ;
Ryan, Jeremy A. ;
Tammareddi, Anupama ;
Moore, Victoria Del Gaizo ;
Deng, Jing ;
Anderson, Kenneth C. ;
Richardson, Paul ;
Tai, Yu-Tzu ;
Mitsiades, Constantine S. ;
Matulonis, Ursula A. ;
Drapkin, Ronny ;
Stone, Richard ;
DeAngelo, Daniel J. ;
McConkey, David J. ;
Sallan, Stephen E. ;
Silverman, Lewis ;
Hirsch, Michelle S. ;
Carrasco, Daniel Ruben ;
Letai, Anthony .
SCIENCE, 2011, 334 (6059) :1129-1133
[3]   Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia [J].
Davids, Matthew S. ;
Deng, Jing ;
Wiestner, Adrian ;
Lannutti, Brian J. ;
Wang, Lili ;
Wu, Catherine J. ;
Wilson, Wyndham H. ;
Brown, Jennifer R. ;
Letai, Anthony .
BLOOD, 2012, 120 (17) :3501-3509
[4]   Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer [J].
Davids, Matthew S. ;
Letai, Anthony .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (25) :3127-3135
[5]   BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents [J].
Deng, Jing ;
Carlson, Nicole ;
Takeyama, Kunihiko ;
Dal Cin, Paola ;
Shipp, Margaret ;
Letai, Anthony .
CANCER CELL, 2007, 12 (02) :171-185
[6]   Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 [J].
Moore, Victoria Del Gaizo ;
Brown, Jennifer R. ;
Certo, Michael ;
Love, Tara M. ;
Novina, Carl D. ;
Letai, Anthony .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (01) :112-121
[7]   An inhibitor of Bcl-2 family proteins induces regression of solid tumours [J].
Oltersdorf, T ;
Elmore, SW ;
Shoemaker, AR ;
Armstrong, RC ;
Augeri, DJ ;
Belli, BA ;
Bruncko, M ;
Deckwerth, TL ;
Dinges, J ;
Hajduk, PJ ;
Joseph, MK ;
Kitada, S ;
Korsmeyer, SJ ;
Kunzer, AR ;
Letai, A ;
Li, C ;
Mitten, MJ ;
Nettesheim, DG ;
Ng, S ;
Nimmer, PM ;
O'Connor, JM ;
Oleksijew, A ;
Petros, AM ;
Reed, JC ;
Shen, W ;
Tahir, SK ;
Thompson, CB ;
Tomaselli, KJ ;
Wang, BL ;
Wendt, MD ;
Zhang, HC ;
Fesik, SW ;
Rosenberg, SH .
NATURE, 2005, 435 (7042) :677-681
[8]   Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease [J].
Roberts, Andrew W. ;
Seymour, John F. ;
Brown, Jennifer R. ;
Wierda, William G. ;
Kipps, Thomas J. ;
Khaw, Seong Lin ;
Carney, Dennis A. ;
He, Simon Z. ;
Huang, David C. S. ;
Xiong, Hao ;
Cui, Yue ;
Busman, Todd A. ;
McKeegan, Evelyn M. ;
Krivoshik, Andrew P. ;
Enschede, Sari H. ;
Humerickhouse, Rod .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) :488-496
[9]  
Souers AJ, 2013, NAT MED
[10]   Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML [J].
Thanh-Trang Vo ;
Ryan, Jeremy ;
Carrasco, Ruben ;
Neuberg, Donna ;
Rossi, Derrick J. ;
Stone, Richard M. ;
DeAngelo, Daniel J. ;
Frattini, Mark G. ;
Letai, Anthony .
CELL, 2012, 151 (02) :344-355
1